These data suggest that high-level FGF2 may decrease HSC pool by negatively regulating stem cell niches and decrease marrow cellularity by attenuating BM retention capacity, while confined FGF2 expression substantially ameliorates these effects and thus prevents severe anemia. The gene discussed is FGF2; the disease is anemia.